Patients Stopping Anti-Obesity Injections Put On Weight at a Quadrupled Rate Compared to Dieters

New research reveals that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt traditional lifestyle programs.

Findings released in a leading health publication shows that while obese individuals often shed about a fifth of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month after stopping.

"People purchasing these drugs need to be cognizant of the risk of quick weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.

That rate of regain means a reversion to pre-treatment weight within about 18 months.

Weighing Treatments

The research, which looked at 37 of studies involving over 9,000 of patients, compared the results of these new drugs with conventional dieting.

Scientists point out that people who shed pounds through lifestyle changes alone typically have a less rapid weight regain—perhaps 0.1 kg a month—after stopping.

The Reason for the Quick Rebound

Nutrition scientists suggest the mechanism of the injections explains the heightened rebound.

GLP-1 drugs copy a body's own chemical called GLP-1, which moderates feelings of fullness.

"Artificially providing the hormone concentrations far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.

"Withdrawal of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating far more likely."

A Chronic Condition?

The NHS advise the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.

A number of clinicians say that, due to the likelihood of relapse, the treatment might need to be long-term.

This perspective is reinforced by pharmaceutical companies, who note that the results "highlight the long-term character of obesity," comparing it to managing diseases like hypertension.

User Experiences

Individuals who have stopped the jabs explain a powerful resurgence of appetite.

"It was like a trigger activating and you're instantly starving," said one woman.

The struggle is worsened if patients have not established permanent lifestyle or habit modifications during therapy.

Growing Use

Survey data suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.

• Use is higher among females compared to men.
• The middle-aged demographic shows the highest level of interest.
• Many obtain the drugs through private prescriptions rather than the NHS.

Finally, researchers emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and long-term success likely depends on combined behavioural changes.